Citations

Clear

16280 citation(s) found for "Yu, David".

Mirror aneurysms: a reflection on natural history
Meissner, Irene, Torner, James C., Huston, John , Rajput, Michele L., Wiebers, David O. , Jones, Lyell K. , Brown, Robert D., _, _, Torner, James C. , _, _, Jones, Lyell K

Mayo Clinic

Journal of Neurosurgery | March 9, 2012 | Volume: 116 | Issue: 6 | Pages: 1238-1241

10.3171/2012.1.jns11779 | PMID 22404675 Get It

Object Investigators conducting the International Study of Unruptured Intracranial Aneurysms, sponsored by the National Institutes of Health, sought to evaluate predictors of future hemorrhage in patients who had unruptured mirror aneurysms. These paired aneurysms in bilateral arterial positions mirror each other; their natural history is unknown. Methods Centers in the US, Canada, and Europe enrolled patients for prospective assessment of unruptured intracranial aneurysms. Central radiological review confirmed the presence or absence of mirror aneurysms in patients without a history of prior subarachnoid hemorrhage (SAH) (Group 1). Outcome at 1 and 5 years and aneurysm characteristics are compared. Results Of 3120 patients with aneurysms treated in 61 centers, 376 (12%) had mirror aneurysms, which are more common in women than men (82% [n = 308] vs 73% [n = 1992], respectively; p <0.001) and in patients with a family history of aneurysm or SAH (p <0.001). Compared with patients with nonmirror saccular aneurysms, a greater percentage of patients with mirror aneurysms had larger (>10 mm) aneurysms (mean maximum diameter 11.7 vs 10.4 mm, respectively; p <0.001). The most common distribution for mirror aneurysms was the middle cerebral artery (34% [126 patients]) followed by noncavernous internal carotid artery (32% [121]), posterior communicating artery (16% [60]), cavernous internal carotid artery (13% [48]), anterior cerebral artery/anterior communicating artery (3% [13]), and vertebrobasilar circulation (2% [8]). When these patients were compared with patients without mirror aneurysms, no statistically significant differences were found in age (mean age 54 years in both groups), blood pressure, smoking history, or cardiac disease. Aneurysm rupture rates were similar (3.0% for patients with mirror aneurysms vs 2.8% for those without). Conclusions Overall, patients with mirror aneurysms were more likely to be women, to report a family history of aneurysmal SAH, and to have larger aneurysms. The presence of a mirror aneurysm was not an independent predictor of future SAHs.
Patellofemoral arthroplasty, where are we today?
Magnussen, Robert A. , Dahm, Diane L., Lustıg, Sébastien , Parker, David Anthony

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | March 9, 2012 | Volume: 20 | Issue: 7 | Pages: 1216-1226

10.1007/s00167-012-1948-z | PMID 22407183 Get It

AbstractPurposePatellofemoral arthroplasty remains controversial, primarily due to the high failure rates reported with early implants. Numerous case series have been published over the years detailing results of various first‐ and second‐generation implants. The purpose of this work is to summarize results published to date and identify common themes regarding implants, surgical techniques, and indications in order to maximize results of future procedures.MethodsA comprehensive review of the MEDLINE database was carried out to identify all clinical studies related to patellofemoral arthroplasty.ResultsFirst‐generation resurfacing implants were associated with relatively high failure rates in the medium term. Second‐generation implants, with femoral cuts based on TKA designs have yielded more promising medium‐term results. Surgical indications are specific and must be carefully followed to minimize poor results. Short‐term complications are generally related to patellar maltracking, while long‐term complications are generally related to progression of osteoarthritis in the tibiofemoral joint. Implant loosening and polyethylene wear are rarely reported. Short‐term results are favourable for new technology including custom implants and computer navigated surgery.ConclusionsOverall, recent improvements in implant design and surgical techniques have resulted in improvements in short‐ and medium‐term results. More work is required to assess the long‐term outcomes of modern implant designs.Level of evidenceIV.
Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome
Camilleri, Michael , Katzka, David A.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | March 9, 2012 | Volume: 302 | Issue: 10 | Pages: G1075-G1084

10.1152/ajpgi.00537.2011 | PMID 22403795 Get It

The objectives of this review are twofold. Our first objective is to evaluate the evidence supporting a role for genetics in irritable bowel syndrome (IBS). Specific examples of the associations of genetic variation and symptoms, syndromes, and intermediate phenotypes, including neurotransmitter (serotonergic, α2-adrenergic, and cannabinoid) mechanisms, inflammatory pathways (IL-10, TNFα, GNβ3, and susceptibility loci involved in Crohn's disease), and bile acid metabolism, are explored. The second objective is to review pharmacogenetics in IBS, with the focus on cytochrome P-450 metabolism of drugs used in IBS, modulation of motor and sensory responses to serotonergic agents based on the 5-hydroxytryptamine (5-HT) transporter-linked polymorphic region ( 5-HTTLPR) and 5-HT3genetic variants, responses to a nonselective cannabinoid agonist (dronabinol) based on cannabinoid receptor ( CNR1) and fatty acid amide hydrolase ( FAAH) variation, and responses to a bile acid (sodium chenodeoxycholate) and bile acid binding (colesevelam) based on klothoβ ( KLB) and fibroblast growth factor receptor 4 ( FGFR4) variation. Overall, there is limited evidence of a genetic association with IBS; the most frequently studied association is with 5-HTTLPR, and the most replicated association is with TNF superfamily member 15. Most of the pharmacogenetic associations are reported with intermediate phenotypes in relatively small trials, and confirmation in large clinical trials using validated clinical end points is still required. No published genome-wide association studies in functional gastrointestinal or motility disorders have been published.
Early Detection of an Underperforming Implantable Cardiovascular Device Using an Automated Safety Surveillance Tool
Mugglin, Andrew S. , Friedman, Paul A. , Kramer, Daniel B. , Kallinen, Linda M., McGriff, Deepa, Hayes, David L. , Hauser, Robert G.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 7, 2012 | Volume: 5 | Issue: 2 | Pages: 189-196

10.1161/circoutcomes.111.962621 | PMID 22396584 Get It

Background— Postmarket medical device surveillance in the United States depends largely on voluntary reporting of adverse events. Consequently, early safety signals may be missed, exposing patients to potentially hazardous products. The aim of this study was to assess the feasibility of using an automated safety surveillance tool to detect early signals that a marketed implantable cardiac device was underperforming. Methods and Results— For this purpose, we performed simulated prospective monthly full-cohort and propensity-matched comparative survival analyses on our 3-center database of Sprint Fidelis and Quattro Secure implantable cardioverter-defibrillator leads, using a commercially available automated surveillance tool that was preset to trigger an alert if the log rank probability value was <0.05. During the study, 84 of 1035 Fidelis (8.1%) and 23 of 1675 Quattro (1.4%) leads failed. The simulated full-cohort analysis triggered a sustained alert for Fidelis leads beginning 13 months after the first implant and 2 years before Fidelis leads were removed from the market. Of the 1035 patients who had Fidelis leads, up to 969 (93.6%) were successfully matched to Quattro patients. In the propensity-matched analysis, the alert triggered 22 months after the first Fidelis implant and more than 1 year before the lead was recalled. Conclusions— An active automated safety surveillance system could have identified this implantable cardiovascular device problem substantially sooner than was achieved through existing postmarket surveillance methods. Such a tool, when applied to clinical registries and remote monitoring databases, may limit the exposure of large populations to underperforming and potentially hazardous cardiovascular devices.
Gene Set Analysis of Survival Following Ovarian Cancer Implicates Macrolide Binding and Intracellular Signaling Genes
Jenkins, Gregory D. , Tsai, Ya-Yu, Song, Honglin , Bolton, Kelly L. , Fenstermacher, David, Ramus, Susan J. , Cunningham, Julie M. , Vierkant, Robert A. , Chen, Zhihua , Chen, Y. Ann , Iversen, Ed , Menon, Usha , Schildkraut, Joellen M. , Sutphen, Rebecca , Gayther, Simon A. , Hartmann, Lynn C. , Sellers, Thomas A. , Goode, Ellen L. , Fridley, Brooke L. , Tyrer, Jonathan P. , Gentry‐Maharaj, Aleksandra , Pharoah, Paul D.P. , Ramus, Susan J , Vierkant, Robert A , Menon, Usha , Bolton, Kelly L

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 7, 2012 | Volume: 21 | Issue: 3 | Pages: 529-536

10.1158/1055-9965.epi-11-0741 | PMID 22302016 Get It

Abstract Background: Genome-wide association studies (GWAS) for epithelial ovarian cancer (EOC), the most lethal gynecologic malignancy, have identified novel susceptibility loci. GWAS for survival after EOC have had more limited success. The association of each single-nucleotide polymorphism (SNP) individually may not be well suited to detect small effects of multiple SNPs, such as those operating within the same biologic pathway. Gene set analysis (GSA) overcomes this limitation by assessing overall evidence for association of a phenotype with all measured variation in a set of genes. Methods: To determine gene sets associated with EOC overall survival, we conducted GSA using data from two large GWAS (N cases = 2,813, N deaths = 1,116), with a novel Principal Component-Gamma GSA method. Analysis was completed for all cases and then separately for high-grade serous histologic subtype. Results: Analysis of the high-grade serous subjects resulted in 43 gene sets with P &lt; 0.005 (1.7%); of these, 21 gene sets had P &lt; 0.10 in both GWAS, including intracellular signaling pathway (P = 7.3 × 10−5) and macrolide binding (P = 6.2 × 10−4) gene sets. The top gene sets in analysis of all cases were meiotic mismatch repair (P = 6.3 × 10−4) and macrolide binding (P = 1.0 × 10−3). Of 18 gene sets with P &lt; 0.005 (0.7%), eight had P &lt; 0.10 in both GWAS. Conclusion: This research detected novel gene sets associated with EOC survival. Impact: Novel gene sets associated with EOC survival might lead to new insights and avenues for development of novel therapies for EOC and pharmacogenomic studies. Cancer Epidemiol Biomarkers Prev; 21(3); 529–36. ©2012 AACR.
A 21-year-old woman with multiple cancers and a new brain lesion
Schiff, David , Lam, E.M., Parisi, J. E., Giannini, C., Uhm, Joon H. , Kantarci, Orhun H. , Keegan, B. Mark

Mayo Clinic

Neurology | March 6, 2012 | Volume: 78 | Issue: 10 | Pages: 743-749

10.1212/wnl.0b013e318248e59c | PMID 22391604 Get It

Clinical Practice Guideline
Stachler, Robert J., Chandrasekhar, Sujana S. , Archer, Sanford M., Schwartz, Seth, Barrs, David M., Fife, Terry D., Ford, Peg, Ganiats, Théodore G. , Hollingsworth, Deena B., Lewandowski, Christopher , Montano, Joseph J., Saunders, James E., Tucci, Debara L. , Valente, Michael , Warren, Barbara, Yaremchuk, Kathleen , Rosenfeld, Richard M. , Brown, Steven Ross , Robertson, Peter J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | March 1, 2012 | Volume: 146 | Issue: S3 | Pages: No page available

10.1177/0194599812436449 | PMID 22383545 Get It

Objective Sudden hearing loss (SHL) is a frightening symptom that often prompts an urgent or emergent visit to a physician. This guideline provides evidence‐based recommendations for the diagnosis, management, and follow‐up of patients who present with SHL. The guideline primarily focuses on sudden sensorineural hearing loss (SSNHL) in adult patients (aged 18 and older). Prompt recognition and management of SSNHL may improve hearing recovery and patient quality of life (QOL). Sudden sensorineural hearing loss affects 5 to 20 per 100,000 population, with about 4000 new cases per year in the United States. This guideline is intended for all clinicians who diagnose or manage adult patients who present with SHL. Purpose The purpose of this guideline is to provide clinicians with evidence‐based recommendations in evaluating patients with SHL, with particular emphasis on managing SSNHL. The panel recognized that patients enter the health care system with SHL as a nonspecific, primary complaint. Therefore, the initial recommendations of the guideline deal with efficiently distinguishing SSNHL from other causes of SHL at the time of presentation. By focusing on opportunities for quality improvement, the guideline should improve diagnostic accuracy, facilitate prompt intervention, decrease variations in management, reduce unnecessary tests and imaging procedures, and improve hearing and rehabilitative outcomes for affected patients. Results The panel made strong recommendations that clinicians should (1) distinguish sensorineural hearing loss from conductive hearing loss in a patient presenting with SHL; (2) educate patients with idiopathic sudden sensorineural hearing loss (ISSNHL) about the natural history of the condition, the benefits and risks of medical interventions, and the limitations of existing evidence regarding efficacy; and (3) counsel patients with incomplete recovery of hearing about the possible benefits of amplification and hearing‐assistive technology and other supportive measures. The panel made recommendations that clinicians should (1) assess patients with presumptive SSNHL for bilateral SHL, recurrent episodes of SHL, or focal neurologic findings; (2) diagnose presumptive ISSNHL if audiometry confirms a 30‐dB hearing loss at 3 consecutive frequencies and an underlying condition cannot be identified by history and physical examination; (3) evaluate patients with ISSNHL for retrocochlear pathology by obtaining magnetic resonance imaging, auditory brainstem response, or audiometric follow‐up; (4) offer intratympanic steroid perfusion when patients have incomplete recovery from ISSNHL after failure of initial management; and (5) obtain follow‐up audiometric evaluation within 6 months of diagnosis for patients with ISSNHL. The panel offered as options that clinicians may offer (1) corticosteroids as initial therapy to patients with ISSNHL and (2) hyperbaric oxygen therapy within 3 months of diagnosis of ISSNHL. The panel made a recommendation against clinicians routinely prescribing antivirals, thrombolytics, vasodilators, vasoactive substances, or antioxidants to patients with ISSNHL. The panel made strong recommendations against clinicians (1) ordering computerized tomography of the head/brain in the initial evaluation of a patient with presumptive SSNHL and (2) obtaining routine laboratory tests in patients with ISSNHL.
Cerebrovascular pathology in cognitive impairment
Knopman, David S.

Mayo Clinic

Neurology | March 1, 2012 | Volume: 78 | Issue: 14 | Pages: 1032-1033

10.1212/wnl.0b013e31824e8fb4 | PMID 22377812 Get It

Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine
Lindblad, A. S., Harrington, Molly, Mathew, N. T., Hirtz, Deborah, Silberstein, Stephen D. , Dodick, David W. , Holroyd, Kenneth J.

Mayo Clinic

Neurology | March 1, 2012 | Volume: 78 | Issue: 13 | Pages: 976-984

10.1212/wnl.0b013e31824d5846 | PMID 22377815 Get It